(Total Views: 431)
Posted On: 05/07/2025 7:15:40 PM
Post# of 154633
Re: Carsmax177 #152477
Quote:
For pembrolizumab + standard chemotherapy and sacituzumab govitecan (ASCENT) there are only 2 years of data presented versus the French ESME program had 3 years. Would there be a reason the first two dont have 3 year data?
In the Trodelvy trial the primary outcome was progression free survival tracked for 29.6 months. In the secondary outcomes the follow-up was 30.8 months. They may have tracked data after this point but have no obligation to release it.
(8)
(0)
